Center for Personalized Cancer Therapy and the Department of Biology, The University of Massachusetts, Boston, Boston, MA, 02125, USA.
Curr Urol Rep. 2013 Dec;14(6):628-37. doi: 10.1007/s11934-013-0368-z.
Benign prostatic hyperplasia (BPH) is a major health concern for aging men. BPH is associated with urinary voiding dysfunction and lower urinary tract symptoms (LUTS), which negatively affects quality of life. Surgical resection and medical approaches have proven effective for improving urinary flow and relieving LUTS but are not effective for all men and can produce adverse effects that require termination of the therapeutic regimen. Thus, there is a need to explore other therapeutic targets to treat BPH/LUTS. Complicating the treatment of BPH/LUTS is the lack of biomarkers to effectively identify pathobiologies contributing to BPH/LUTS or to gauge successful response to therapy. This review will briefly discuss current knowledge and will highlight new studies that illuminate the pathobiologies contributing to BPH/LUTS, potential new therapeutic strategies for successfully treating BPH/LUTS, and new approaches for better defining these pathobiologies and response to therapeutics through the development of biomarkers and phenotyping strategies.
良性前列腺增生症（BPH）是老年男性的主要健康问题。BPH 与尿流功能障碍和下尿路症状（LUTS）有关，这会降低生活质量。手术切除和药物治疗已被证明可有效改善尿流并缓解 LUTS，但并非对所有男性都有效，并且会产生需要终止治疗方案的不良反应。因此，需要探索其他治疗靶点来治疗 BPH/LUTS。使 BPH/LUTS 的治疗复杂化的是缺乏有效的生物标志物来有效识别导致 BPH/LUTS 的病理生物学，或评估对治疗的成功反应。这篇综述将简要讨论目前的知识，并强调阐明导致 BPH/LUTS 的病理生物学、成功治疗 BPH/LUTS 的潜在新治疗策略，以及通过开发生物标志物和表型策略更好地定义这些病理生物学和对治疗的反应的新方法的新研究。
